Primary and secondary prevention of cardiovascular disease in diabetes with aspirin

Diabetes and Vascular Disease Research

Volumn 9, Issue 4, 2012, Pages 243-244

  Ajjan, Ramzi A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; INSULIN; SIMVASTATIN;

BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; PRACTICE GUIDELINE; PRIMARY PREVENTION; SECONDARY PREVENTION;

ANIMALS; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 84866711271     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112455534     Document Type: Editorial

References (14)

1. Grant PJ. Inflammatory, atherothrombotic aspects of type 2 diabetes. Curr Med Res Opin. 2005 ; 21: S5-12
2. Nandish S, Wyatt J, Bailon O, et al. Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus. Am J Cardiol. 2011 ; 108: 42B - 51B
3. Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res. 2010 ; 7: 251-259
4. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res. 2010 ; 7: 260-273
5. Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv. 2011 ; 4: 180-187
6. N Engl J Med. 1988 ; 318: 924-926
7. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989 ; 321: 129-135
8. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA. 1992 ; 268: 1292-1300
9. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008 ; 337: a1840
10. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008 ; 300: 2134-2141
11. Antiplatelet Trialists' Collaboration. BMJ. 1994 ; 308: 81-106
12. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324: 71-86
13. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010 ; 121: 2694-2701
14. De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012 ; 307: 2286-2294